Article

SABCS: Debu Tripathy Discusses PI3 Kinase Inhibitors in Breast Cancer

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving a PI3 kinase inhibitor showed interesting results.

While the clinical trial involving the investigational agent pictilisib with an aromatase inhibitor had only modest results, interest in this type of targeted therapy remains, particularly in different stages of the disease and in combination with other drugs.

You can read more on the study at "Early Phase Study Finds PI3K Inhibitor Pictilisib Helps a Subset of Advanced Breast Cancer Patients."

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Related Content
Marissa is a “GenXer” living as a “flattie” with metastatic breast cancer since March 2014. Read more of Marissa's blogs here!
June 19th 2025

Why I Don’t Call Myself a Survivor With Metastatic Breast Cancer

Marissa Holzer
Living with metastatic breast cancer, I find it hard to relate to the term “survivor.”
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to immune checkpoint inhibitors: © stock.adobe.com.
May 16th 2025

Leronlimab Linked to Increased PD-L1 in Triple-Negative Breast Cancer

Spencer Feldman
Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to immune checkpoint inhibitors.
Christina McAmis and her children
July 27th 2023

Mother with Stage 4 Breast Cancer and Her Family 'Focus on the Living'

Alex Biese
Christina McAmis’ cancer journey began when she found a lump while breastfeeding. The attorney and mother of three tells the “Cancer Horizons” podcast what the last nine years have been like for her and her family.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Image of breast.
April 30th 2025

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

Ryan Scott
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.